Cargando…

Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex – United States, March 2019 – December 2020

BACKGROUND: COVID-19 stay-at-home orders may reduce access to substance use treatment and naloxone, an opioid overdose reversal drug. The objective of this analysis was to compare monthly trends in pharmacy-based dispensing rates of medications for opioid use disorder (MOUD) (buprenorphine and exten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cremer, Laura J., Board, Amy, Guy, Gery P., Schieber, Lyna, Asher, Alice, Parker, Erin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620097/ https://www.ncbi.nlm.nih.gov/pubmed/35065513 http://dx.doi.org/10.1016/j.drugalcdep.2021.109192

Ejemplares similares

Risk factors for COVID-19 among persons with substance use disorder (PWSUD) with hospital visits – United States, April 2020–December 2020()
por: Board, Amy R., et al.
Publicado: (2022)

Vital Signs: Pharmacy-Based Naloxone Dispensing — United States, 2012–2018
por: Guy, Gery P., et al.
Publicado: (2019)

Trends in Out-of-Pocket Costs for and Characteristics of Pharmacy-Dispensed Buprenorphine Medications for Opioid Use Disorder Treatment by Type of Payer, 2015 to 2020
por: Strahan, Andrea E., et al.
Publicado: (2023)

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX)
por: Kunøe, Nikolaj, et al.
Publicado: (2016)

Variation in Adult Outpatient Opioid Prescription Dispensing by Age and Sex — United States, 2008–2018
por: Schieber, Lyna Z., et al.
Publicado: (2020)

Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail
por: Velasquez, Melissa, et al.
Publicado: (2019)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
por: Blazes, Christopher K., et al.
Publicado: (2020)

The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study
por: Choremis, Beatrice, et al.
Publicado: (2019)

Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic
por: Nguyen, Thuy, et al.
Publicado: (2022)

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
por: McCormack, Lindsay, et al.
Publicado: (2021)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
por: Papp, Joan, et al.
Publicado: (2023)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016
por: Meyerson, B.E., et al.
Publicado: (2018)

Increasing proactive co-dispensing of take-home naloxone with prescription opioids at Ontario community pharmacies
por: Qiu Hua Chen, Autumn
Publicado: (2022)

Cost-Effectiveness of Buprenorphine and Naltrexone Treatments for Heroin Dependence in Malaysia
por: Ruger, Jennifer Prah, et al.
Publicado: (2012)

Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic
por: Dadiomov, David, et al.
Publicado: (2022)

Association of Naloxone Coprescription Laws With Naloxone Prescription Dispensing in the United States
por: Sohn, Minji, et al.
Publicado: (2019)

Successful Management of Kratom Use Disorder With Buprenorphine and Naloxone
por: Arhin, Martin, et al.
Publicado: (2023)

Examining the effects of COVID-19 on pharmacy dispensing of naloxone and syringes sales across Massachusetts and New Hampshire
por: Bolivar, Derek, et al.
Publicado: (2023)

Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020
por: Chalasani, Rohan, et al.
Publicado: (2021)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
por: Cook, R. R., et al.
Publicado: (2023)

Association Between a State Law Allowing Pharmacists to Dispense Naloxone Without a Prescription and Naloxone Dispensing Rates
por: Gangal, Neha S., et al.
Publicado: (2020)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
por: Simojoki, Kaarlo, et al.
Publicado: (2008)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Assessment of Medication Dispensing and Extended Community Pharmacy Services
por: Ibrahim, Mohamed Izham Mohamed
Publicado: (2018)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence
por: Mauger, Sofie, et al.
Publicado: (2014)

Low-dose naloxone provides an abuse-deterrent effect to buprenorphine
por: Webster, Lynn R, et al.
Publicado: (2015)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
por: Gawronski, Kristen M, et al.
Publicado: (2014)

Yoga as an Adjunctive Intervention to Medication-Assisted Treatment with Buprenorphine+Naloxone
por: Lander, Laura, et al.
Publicado: (2017)

Sexual dysfunction in men on buprenorphine – naloxone-based substitution therapy
por: Mattoo, Surendra K., et al.
Publicado: (2020)

Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan
por: Goshgarian, Gregory, et al.
Publicado: (2022)

Factors in rural community buprenorphine dispensing
por: Major, Erin G., et al.
Publicado: (2022)

Protocol for the Optimizing Naloxone Dispensing in Pharmacies (ONDP) Online Continuing Education Program: A Randomized Controlled Trial
por: Cid, Ashley, et al.
Publicado: (2022)

From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
por: Tourunen, Jouni, et al.
Publicado: (2010)

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province
por: Sadek, Joseph, et al.
Publicado: (2022)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended‐release naltrexone in a residential setting
por: Mannelli, Paolo, et al.
Publicado: (2022)

Patient Satisfaction with Primary Care Office-Based Buprenorphine/Naloxone Treatment
por: Barry, Declan T., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rt9pqg3tv8uv5rdul1p3oivihu